Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH
21 juin 2021 08h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress
01 juin 2021 08h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference
28 mai 2021 16h05 HE
|
Akero Therapeutics
SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic...
Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
13 mai 2021 07h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero Therapeutics Appoints Yuan Xu to its Board of Directors
26 avr. 2021 08h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero Therapeutics Announces First Patient Randomized for Dosing in Phase 2b Study of Efruxifermin (EFX) in F2/F3 NASH Patients (HARMONY)
23 mars 2021 08h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
22 mars 2021 16h01 HE
|
Akero Therapeutics
-- 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH -- -- 25% of EFX patients (3 of 12) showed NASH resolution -- --...
Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients
22 mars 2021 06h30 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH
14 sept. 2020 07h01 HE
|
89bio, Inc.
All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo Favorable safety and...
89bio to Present at Upcoming Investor Conferences
03 août 2020 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...